Raymond James Financial’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$288M Buy
11,942,054
+267,838
+2% +$7.01M 0.08% 219
2026
Q1
$328M Buy
11,674,216
+187,503
+2% +$4.99M 0.1% 175
2025
Q4
$286M Sell
11,486,713
-9,541
-0.1% -$241K 0.09% 197
2025
Q3
$293M Buy
11,496,254
+710,057
+7% +$17.5M 0.09% 194
2025
Q2
$261M Sell
10,786,197
-101,080
-0.9% -$2.36M 0.09% 206
2025
Q1
$276M Buy
10,887,277
+533,173
+5% +$14M 0.1% 183
2024
Q4
$275M Buy
+10,354,104
New +$281M 0.1% 182

Other funds holding PFE

Raymond James Financial's PFE Position: Q2 2026 in Review

Raymond James Financial increased its Pfizer (PFE) stake by 2.3% in Q2 2026, buying an estimated $7.01M and bringing the position to 11,942,054 shares worth $288M. The position accounts for 0.08% of the portfolio, ranked #219.

Raymond James Financial first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $328M in Q1 2026. 2,840 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Raymond James Financial held 11,942,054 shares of Pfizer worth $288M as of Q2 2026.
  • Raymond James Financial bought 267,838 Pfizer shares in Q2 2026, an estimated $7.01M.
  • Pfizer made up 0.08% of Raymond James Financial's portfolio in Q2 2026, its #219 holding.
  • Raymond James Financial first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Pfizer position peaked at $328M in Q1 2026.
  • 2,840 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.